Cita APA (7a ed.)

G, W., J, Z., M, Z., Q, W., B, C., Y, H., & K, L. (2019). Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation. Dove Medical Press.

Cita Chicago Style (17a ed.)

G, Wang, Zhao J, Zhang M, Wang Q, Chen B, Hou Y, y Lu K. Ferumoxytol and CpG Oligodeoxynucleotide 2395 Synergistically Enhance Antitumor Activity of Macrophages Against NSCLC with EGFRL858R/T790M mutation. Dove Medical Press, 2019.

Cita MLA (8a ed.)

G, Wang, et al. Ferumoxytol and CpG Oligodeoxynucleotide 2395 Synergistically Enhance Antitumor Activity of Macrophages Against NSCLC with EGFRL858R/T790M mutation. Dove Medical Press, 2019.